Published September 15, 2021 | Version v1
Other Open

Supplement to LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia

Authors/Creators

  • 1. Novartis Institutes of Biomedical Research

Description

Supplemental information to the manuscript entitled "LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults with Modest Hypertriglyceridemia"

Files

JCLINENDOMETAB-S-21-015424 R1 Supplement.pdf

Files (391.1 kB)

Name Size Download all
md5:007a04643cb674af89ca7f7d2c3a137e
391.1 kB Preview Download

Additional details

References

  • Rader DJ, Maratos-Flier E, Nguyen A, Hom D, Ferriere M, Li Y, Kompa J, Martic M, Hinder M, Basson CT, Yowe D, Diener J, Goldfine AB; CLLF580X2102 study team. LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia. J Clin Endocrinol Metab. 2021 Aug 25:dgab624. doi: 10.1210/clinem/dgab624. Epub ahead of print. PMID: 34431493.